Want to see SERA full AI Analyst Report?

Sera Prognostics (SERA) Price & Analysis

98 Followers

SERA Stock Chart & Stats

$2.30

$0.42(5.34%)

At close: Jan 08 4:00 PM EST

$2.30

$0.42(5.34%)

Day’s Range― - ―

52-Week Range$1.56 - $3.95

Previous CloseN/A

Volume57.63K

Average Volume (3M)40.22K

Market Cap

$80.28M

Enterprise Value$57.13

Total Cash (Recent Filing)$47.40M

Total Debt (Recent Filing)$2.50M

Price to Earnings (P/E)―

Beta1.25

Next Earnings

Aug 12, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding38,190,968

10 Day Avg. Volume55,279

30 Day Avg. Volume40,220

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)1.86

Price to Sales (P/S)1735.84

P/FCF Ratio-5.34

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$6.00

Price Target Upside160.87% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.66

Revenue Forecast (FY)$361.50K

Bulls Say, Bears Say

Bulls Say

Low Leverage / Conservative Balance SheetLow leverage and modest debt reduce refinancing and solvency risk, giving the company financial flexibility during a multi‑year commercialization effort. A conservative balance sheet supports continuing evidence generation and payer negotiations without immediate pressure to monetize assets.

Strong Cash Runway And Cost-reduction PlanHolding ~$86.8M and a plan to cut ~ $10M in annual opex extends runway through 2029, enabling the company to pursue commercialization, payer engagement and evidence studies over multiple years. This funding buffer materially lowers short‑term financing risk while adoption and reimbursement mature.

Commercial And Payer Engagement ProgressExpanding live partner programs and active payer discussions reflect structural progress toward distribution and reimbursement. Building provider partnerships and multi‑state payer engagement creates durable channels for adoption and is essential to scaling test volumes and securing repeatable revenue streams.

Bears Say

Weak Revenue And Negative Gross ProfitRevenue has fallen materially and gross profit is negative on a trailing basis, indicating the business currently loses money on sales. Without demonstrable unit economics and scale, profitability depends on sustained volume growth and improved reimbursement, which are uncertain and time‑consuming.

Persistent Cash Burn And Negative Operating Cash FlowConsistent negative operating and free cash flows show the company is consuming cash to operate. Prolonged cash burn increases the likelihood of future dilution or program cuts if commercial adoption and payer payments lag, limiting the firm's ability to invest organically in expansion.

Delayed Payer Coverage And Limited Volume VisibilityMulti‑step payer coverage timelines (Medicaid pilot ~2 years) and the company's withholding of test volume KPIs create durable uncertainty around revenue scale and timing. Structural delays in coverage decisions and opaque adoption metrics hinder predictable scaling and planning.

Sera Prognostics News

Sera Prognostics management to meet virtually with Craig-Hallum

Virtual Meeting to be held on July 21 hosted by Craig-Hallum. Published first on TheFly – the ultimate...

6d ago

SERA

Sera Prognostics’ PreTRM Test shows efficacy guiding first-time pregnancy care

Sera Prognostics (SERA) announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis...

12d ago

SERA

Sera Prognostics part of ARPA-H award for birth safety test development

Sera Prognostics (SERA) announced its participation in a multi-institutional research program that was awarded up to $10.4M by...

27d ago

ALGM

SERA

Sera Prognostics Adds Veteran Executive to Board

Sera Prognostics ( ($SERA) ) has issued an update. Sera Prognostics announced on June 30, 2026 that seasoned...

21d ago

SERA

Sera Prognostics Holds 2026 Annual Stockholders Meeting

Sera Prognostics ( ($SERA) ) just unveiled an update. On June 4, 2026, Sera Prognostics, Inc. held its...

2M ago

SERA

Craig-Hallum bullish on Sera Prognostics, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Sera Prognostics (SERA) with a Buy rating and $6 price target...

2M ago

SERA

Sera Prognostics initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Sera Prognostics (SERA) with a Buy rating and $6 price target Published first on...

2M ago

SERA

Sera Prognostics Announces Board Resignation and Transition Plan

The latest update is out from Sera Prognostics ( ($SERA) ). On May 26, 2026, Sera Prognostics director...

2M ago

SERA

Sera Prognostics Balances Cash Strength With Slow Ramp

Sera Prognostics, Inc. (($SERA)) has held its Q1 earnings call. Read on for the main highlights of the...

2M ago

SERA

Sera Prognostics reports Q1 EPS (17c), consensus (17c)

Reports Q1 revenue $14K, consensus $66.67K. “In Q1, our primary focus was building awareness with clinicians and the...

3M ago

SERA

Sera Prognostics Earnings Call: Data-Rich, Revenue-Light

Sera Prognostics, Inc. (($SERA)) has held its Q4 earnings call. Read on for the main highlights of the...

4M ago

SERA

Sera Prognostics reports Q4 EPS (16c), consensus (19c)

Reports Q4 revenue $10K vs. $24K last year. In February 2025, Sera completed an underwritten public offering of...

4M ago

SERA

SERA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Sera Prognostics, Inc. (SERA) is scheduled to report 4th quarter earnings on 03/18/2026, after the market closes. Regarding...

4M ago

SERA

Validating Momentum: PRIME Publication and Emerging Commercial Proof Points Support Sera’s Buy Rating Despite Adoption Risks

William Blair analyst Andrew Brackmann has maintained their bullish stance on SERA stock, giving a Buy rating on...

5M ago

SERA

SERA FAQ

What was Sera Prognostics’s price range in the past 12 months?

Sera Prognostics lowest stock price was $1.56 and its highest was $3.95 in the past 12 months.

What is Sera Prognostics’s market cap?

Sera Prognostics’s market cap is $80.28M.

When is Sera Prognostics’s upcoming earnings report date?

Sera Prognostics’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.

How were Sera Prognostics’s earnings last quarter?

Sera Prognostics released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.003.

Is Sera Prognostics overvalued?

According to Wall Street analysts Sera Prognostics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sera Prognostics pay dividends?

Sera Prognostics does not currently pay dividends.

What is Sera Prognostics’s EPS estimate?

Sera Prognostics’s EPS estimate is -0.15.

How many shares outstanding does Sera Prognostics have?

Sera Prognostics has 38,190,968 shares outstanding.

What happened to Sera Prognostics’s price movement after its last earnings report?

Sera Prognostics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went up 6.077%.

Which hedge fund is a major shareholder of Sera Prognostics?

Currently, no hedge funds are holding shares in SERA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sera Prognostics Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-20.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sera Prognostics

Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.

Sera Prognostics (SERA) Earnings & Revenues

Historic Earnings Reports

SERA Stock 12 Month Forecast

Average Price Target

$6.00

▲(160.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.335384615384615,2.6407692307692305,2.9461538461538463,3.2515384615384617,3.556923076923077,3.8623076923076924,4.167692307692308,4.473076923076923,4.7784615384615385,5.083846153846154,5.389230769230769,5.6946153846153855,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.335384615384615,2.6407692307692305,2.9461538461538463,3.2515384615384617,3.556923076923077,3.8623076923076924,4.167692307692308,4.473076923076923,4.7784615384615385,5.083846153846154,5.389230769230769,5.6946153846153855,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.03,2.335384615384615,2.6407692307692305,2.9461538461538463,3.2515384615384617,3.556923076923077,3.8623076923076924,4.167692307692308,4.473076923076923,4.7784615384615385,5.083846153846154,5.389230769230769,5.6946153846153855,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >